Copyright: Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！ 京ICP备19006400号-1 Powered by 300.cn
Jiuzhitang joins hands with top US pharmaceutical company to enter the stem cell industry
Jiuzhitang Yonghe Qihang fund launched by Jiuzhitang signed an investment agreement with Stemedica Cell Technologies, Inc. on September 14. Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as Jiuzhitang Maker) will introduce the stem cell production technologies and manufacturing platform developed by world's top stem cell company. Its production facility under construction is expected to be put into use in 2019.
Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. is the sole Chinese recipient of Stemedica's stem cell technologies. Located in Dan Diego, where a great many biotechnical and pharmaceutical companies gather, Stemedica is the first US clinical research agency with approval to treat Alzheimer’s using stem cells, one of the few US biomedical companies approved by FDA to conduct studies on stem cell drugs, and one of the world’s few corporations that are capable of manufacturing both human bone marrow-derived mesenchymal stem cells and human neural stem cells.
Stemedica's hypoxic manufacturing process has demonstrated excellent safety and therapeutic efficacy in clinical trials. In recent years, Stemedica has conducted six clinical trials of stem cell therapy in the United States: ischemic stroke, chronic heart failure, Alzheimer's disease, skin photoaging, acute myocardial infarction, and traumatic brain injury, among which those on ischemic stroke and chronic heart failure have progressed to Phase II and published several high-level academic papers, and the clinical study on Alzheimer’s is the first approved effort in the States that uses stem cells to treat this medical condition.
Jiuzhitang (Maker) plans to conduct stem cell clinical studies on neurological, cardiovascular and cerebrovascular diseases based on the results of Stemedica's clinical trials, so as to promote the early availability of stem cell drugs in China market.